Cardiol Therapeutics Inc - Class A

Research Cardiol Therapeutics Inc - Class A (CRDL) on Bullrun: market cap USD 118.73M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCRDL
• ExchangeNASDAQ
• CountryCanada
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Market capUSD 118.73M
• Financial periodQ1 2026
• Net income-USD 10.82M
• Free cash flow-USD 7.57M

Valuation Snapshot

latest market cap is USD 118.73M.

About Cardiol Therapeutics Inc - Class A

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Frequently asked questions

What is Cardiol Therapeutics Inc - Class A's market cap?

Cardiol Therapeutics Inc - Class A's market capitalization is USD 118.73M.

What does Cardiol Therapeutics Inc - Class A do?

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.